Affimed provided a data update from the ongoing phase 1/2 study of the company’s lead innate cell engager AFM13 precomplexed with cord blood-derived natural killer cells in patients with CD30-positive relapsed or refractory Hodgkin and Non-Hodgkin lymphomas. Results from the study continue to demonstrate high objective and complete response rates with a well-tolerated safety profile. In 31 patients with Hodgkin lymphoma treated at the RP2D, an ORR of 97% and a CR rate of 77% were observed. In four non-Hodgkin lymphoma patients treated at the RP2D, three objective responses, including one CR in a patient with peripheral T-cell lymphoma, were observed. Across all 35 patients treated at the RP2D, a 94% ORR and a CR rate of 71% were observed.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AFMD:
- Affimed Plunges after Detailing New Plans
- Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
- Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
- Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
- Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
